JPMorgan Reiterates Overweight Rating on Ionis Pharmaceuticals (IONS)

August 31, 2026 2:41 AM

JPMorgan analyst Jessica Fye reiterated an Overweight rating and $76.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)The analyst comments: “Coming ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found